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Abbreviations
and Acronyms
BP = bioabsorbable polymers
BES = biolimus-eluting
stent(s)
CI = credible interval
CoCr-EES = cobalt-chromium
everolimus-eluting stent(s)
DP = durable polymers
OR = odds ratio
PC-ZES = phosphorylcholine-
based zotarolimus-eluting
stent(s)
PES = paclitaxel-eluting
stent(s)
PtCr-EES = platinum
chromium everolimus-eluting
stent(s)
RCT = randomized controlled
trial
SES = sirolimus-eluting
stent(s)
ST = stent thrombosis
TVR = target vessel
revascularizations
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300thrombosis (ST) (3). Human au-
topsy studies have identiﬁed
the durable polymers (DP) of
these ﬁrst-generation drug-eluting
stents (DES) as possible triggers
for chronic vessel inﬂammation,
delayed hypersensitivity reactions,
and chronic ﬁbrin deposition, re-
sulting in impaired stent strut
endothelialization, delayed arte-
rial healing, altered ﬂow dyna-
mics, and an increased risk of very
late ST (4,5).
To improveDES safety, second-
generation DES have been devel-
oped with more biocompatible
DPs, or bioabsorbable polymers
(BP), which are eventually bio-
resorbed, rendering the stent
surface more similar to BMS
and free of a chronic inﬂamma-
tory stimulus. Some studies have
shown that BP-based DES are
more effective than BMS (6)
and, by reducing the risk of
very late ST, perhaps safer thanﬁrst-generation DES (7). However, second-generation ﬂuo-
rinated DP-based cobalt-chromium everolimus-eluting stents
(CoCr-EES) (Xience V and Promus, Boston Scientiﬁc) and
platinum chromium everolimus-eluting stents (PtCr-EES)
(Promus Element, Boston Scientiﬁc) have been associated
with lower rates of early, late, and very late ST compared with
ﬁrst-generation DES and even BMS (8), challenging the
notion that BP are required to minimize the risk of ST.
The relative safety and efﬁcacy of BP-based DES and
other second-generation DP-DES have been incompletely
characterized. Studies comparing these new devices have in
general been insufﬁciently powered to determine signiﬁcant
differences in individual components of safety (death,
cardiac death, myocardial infarction [MI], and ST) and
efﬁcacy (TVR) (9). Network meta-analyses and mixed
treated comparisons are novel research methods capable of
comparing different treatments with a common reference
treatment, and their role in clinical research has been
established (10). Accordingly, we performed an updated,
contemporary, comprehensive network meta-analysis to
investigate whether there are major differences in safety and
efﬁcacy between BP-based DES, other ﬁrst- and second-
generation DES, and BMS.Methods
Objectives, deﬁnitions, and study design. Because in-
depth comparisons in clinical outcomes between ﬁrst-
generation DP-DES, second-generation DP-DES, and
BMS have already been reported (8,11), the primary objectiveof this meta-analysis was to compare BP-based DES with
the other types of stents. Biolimus-eluting stents (BES)
(Biomatrix [Biosensors International, Singapore] and Nobori
[Terumo Corporation, Tokyo, Japan]) are the BP-based
DES that have been most extensively investigated and are
currently the most widely used; therefore, we only included
studies using these BP-DES. As DES comparators, we
considered only U.S. Food and Drug Administration-
approved stents, because these are the devices with the most
robust demonstration of safety and efﬁcacy. Therefore, stents
considered in this meta-analysis were BP-BES, SES, PES,
CoCr-EES, PtCr-EES, phosphorylcholine polymer-based
fast-release zotarolimus-eluting stents (PC-ZES) (En-
deavor, Medtronic, Minneapolis, Minnesota), and C10/
C19/PVP polymer based slow-release ZES (Resolute,
Medtronic). We were interested in examining the compara-
tive outcomes at 1-year follow-up (the time period when the
greatest amount of follow-up data are available) and beyond
1-year, with the latest follow-up data reported from each
study. Safety endpoints included death, cardiac death, MI,
death or MI, cardiac death or MI, and ST according to the
deﬁnite and deﬁnite/probable criteria of the Academic
Research Consortium (12). Stent thrombosis was further
stratiﬁed as early (30 days), late (31 days to 1 year), or very
late (beyond 1 year). The efﬁcacy endpoint was TVR. The
present review was performed according to PRISMA
(Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) statements (13).
Data source and study selection. Relevant randomized
controlled trials (RCTs) to include in this meta-analysis
were searched through MEDLINE/PubMed; the Co-
chrane Collaboration database; the EMBASE, TCTMD,
ClinicalTrials.gov, Clinical Trial Results, and American
College of Cardiology CardioSource online databases; and
abstracts and presentations from major cardiovascular
meetings, with the key words: drug-eluting stent, biolimus-
eluting stent, everolimus-eluting stent, paclitaxel-eluting
stent, sirolimus-eluting stent, zotarolimus-eluting stent,
and bare-metal stent. The RCTs comparing 2 or 3 different
DES or DES with BMS were identiﬁed and included in the
meta-analysis. Two investigators (T.P. and D.D.R.) inde-
pendently reviewed the titles, abstracts, and studies to
determine whether they met the inclusion criteria. Conﬂicts
between reviewers were resolved by consensus. No language,
publication date, or publication status restrictions were
imposed. The most updated or most inclusive data for
a given study were chosen for abstraction. Internal validity of
RCTs was assessed by evaluating concealment of allocation,
blind adjudication of clinical events, and inclusion of all
randomized patients in the analysis according to the
intention-to-treat principle.
Statistical analysis. Dichotomous outcome variables at
speciﬁc time-points were compared with posterior median
odds ratios (ORs) with 95% Bayesian credible intervals (CIs)
by means of network meta-analysis with a random-effect
model with WinBUGS (version 1.4.3, MRC Biostatistics
Figure 1
Evidence Network Between Stents Included in the
Meta-Analysis
BMS ¼ bare-metal stent(s); BP-BES ¼ bioabsorbable polymer biolimus-eluting
stent(s); CoCr-EES ¼ cobalt-chromium everolimus-eluting stent(s); PC-ZES ¼
phosphorylcholine polymer-based zotarolimus-eluting stent(s); PES ¼ paclitaxel-
eluting stent(s); PtCr-EES ¼ platinum-chromium everolimus-eluting stent(s); Re-
ZES ¼ Resolute zotarolimus eluting stent(s); SES ¼ sirolimus-eluting stent(s).
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301Unit, Cambridge, United Kingdom). We relied on Bayesian
inference with Monte Carlo Markov Chain simulations
with Gibbs sampling for all computations, including the
network estimates (combining direct and indirect evidence),
as well as the ORs and absolute risk estimates. Each analysis
was based on non-informative priors for effect sizes and
precision. Convergence and lack of auto-correlation were
checked and conﬁrmed after a 50,000-simulation burn-in
phase, and, ﬁnally, direct probability statements were
based on an additional 100,000-simulation phase. Model ﬁt
was appraised by computing and comparing estimates for
deviance and deviance information criterion. Pair-wise
inconsistency and inconsistency between direct and indi-
rect effect estimates were assessed with the I2 statistic, with
values <25%, 25% I2 50%, and >50%, respectively,
representing mild, moderate, and severe inconsistency.
Extent of small study effects/publication bias was assessed
by visual inspection of funnel plots. In addition, to inves-
tigate whether there might be differences in clinical
outcomes beyond 1 year, given the variability in the length
of follow-up reported by each trial, we also determined
hazard ratios for event rates/100 patient-years between
different stent types by means of a weighted Poisson
regression analysis.
Results
Evidence network. The ﬂow diagram of the study analysis
is shown in Online Figure 1. Of 2,784 potentially relevantarticles initially screened, 89 trials met the inclusion criteria
and were included in the ﬁnal meta-analysis, comprising
a total of 85,490 randomized patients (Online Table 1). The
major characteristics of the included trials appear in Online
Table 2. The evidence network is shown in Figure 1. The
major inclusion and exclusion criteria and internal validity
assessment for each trial are reported in Online Table 3. The
clinical characteristics of patients enrolled in the RCTs
included in the meta-analysis are reported in Online
Table 4.
1-year clinical outcomes. Eighty-two studies with 70,127
patients contributed to the analysis of 1-year mortality, 70
studies with 61,887 patients contributed to the analysis of 1-
year cardiac mortality; 83 studies with 73,267 patients
contributed to the analysis of 1-year MI; 64 studies with
78,720 patients contributed to the analysis of 1-year deﬁnite
ST; and 64 studies with 73,176 patients contributed to the
analysis of 1-year deﬁnite/probable ST. As shown in Online
Table 5, no signiﬁcant differences in 1-year rates of
mortality or cardiac mortality were apparent between BP-
BES and the other stent types. However, BP-BES were
associated with signiﬁcantly lower 1-year rates of cardiac
death/MI (Fig. 2A), MI (Fig. 2B), and TVR (Fig. 2C) than
BMS and signiﬁcantly lower 1-year rates of TVR than PC-
ZES (Fig. 2C). Of note, BP-BES had signiﬁcantly higher
1-year rates of deﬁnite ST compared with CoCr-EES
(Fig. 2D). When the broader deﬁnition of deﬁnite/prob-
able ST was considered, BP-BES was associated with
signiﬁcantly lower rates of 1-year deﬁnite/probable ST than
BMS (Fig. 2E), with nonsigniﬁcant differences compared
with other DES. Differences in 1-year rates of mortality,
MI, TVR, and ST between other stent types are reported in
Online Tables 5 to 7.
Long-term (>1 year) clinical outcomes. The latest follow-
up available for each study is reported in Online Table 2.
Data beyond 1 year were present in 44 studies with 50,815
patients for late mortality; in 43 studies with 50,643 patients
for late cardiac mortality; in 46 studies with 50,836 patients
for late MI; in 38 studies with 49,552 patients for late
deﬁnite ST; and in 40 studies with 47,695 patients for late
deﬁnite/probable ST. No signiﬁcant differences in long-
term mortality or cardiac mortality were apparent between
any of the stent types (Online Table 5). As seen in
Figures 3A to 3E, BP-BES were associated, by Poisson
regression analysis, with signiﬁcantly lower rates of cardiac
death/MI, MI, and TVR/100 patient-years compared with
both BMS and PES and lower rates of long-term TVR than
PC-ZES. In contrast, BP-BES were associated with sig-
niﬁcantly higher rates of long-term deﬁnite ST than CoCr-
EES (Fig. 3D). When the broader deﬁnition of deﬁnite/
probable ST was considered, BP-BES were associated with
a lower risk of long-term deﬁnite/probable ST than BMS
and PES, with nonsigniﬁcantly different rates when
compared with other stent types (Fig. 3E). Differences in
long-term mortality, MI, TVR, and ST between other stent
types are reported in Online Tables 5 to 7.
Figure 2 1-Year Pooled ORs and 95% CIs of BES Versus Other Stent Types
One-year pooled odds ratio (OR) and 95% credible intervals (CIs) of BES versus other stent types determined by the network meta-analysis for (A) cardiac death or myocardial
infarction; (B) myocardial infarction; (C) target vessel revascularization; (D) deﬁnite stent thrombosis; and (E) deﬁnite/probable stent thrombosis. Abbreviations as in Figure 1.
Continued on the next page.
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302Early, late, and very late ST. As shown in Online Table 7
and Online Figure 2, signiﬁcant time-related differences in
deﬁnite and deﬁnite/probable ST were apparent between the
different stent types. In general CoCr-EES were associated
with the lowest rates of deﬁnite ST in the early (30 days) and
late (between 30 days and 1 year) periods. In the very late period
(>1 year), PES and SES had higher rates of deﬁnite ST than
other stent types.TheBP-BES,CoCr-EES, andPC-ZEShad
lower very late deﬁnite ST rates than BMS. No signiﬁcantdifferences were present between BP-BES and other second-
generation DES in the risk of very late deﬁnite ST. Of note,
all slow-release limus-eluting stents were associated with lower
rates of early deﬁnite probable ST compared with BMS.
Additional analyses. Sensitivity analysis on the basis of
ﬁxed effect models or performed after excluding studies
enrolling patients with diabetes or studies performed in Asia
did not signiﬁcantly change the results of the meta-analysis
(Online Tables 8 to 10). Visual inspection of funnel plots
Figure 2 Continued
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303did not suggest any small study effects or publication bias
(Online Fig. 3). Only mild or moderate statistical hetero-
geneity was found for all pair-wise analyses. Direct and
indirect estimates were consistent for all main analyses
(I2 <25%).
Discussion
The BP-based DES and second-generation DES coated
with biocompatible DP have been shown to be safer and
more effective than both BMS and ﬁrst-generation DES
(7,8,11). However, few studies have compared BP-BES
versus second-generation DP-DES (9), and therefore their
relative safety and efﬁcacy remains undetermined. The
present report is the largest and most comprehensive study
to date comparing the safety and efﬁcacy proﬁle of BP-
based BES with other stent types, including ﬁrst-
generation DES, second-generation DES, and BMS. The
principal ﬁndings are: 1) BP-BES were associated with
signiﬁcantly lower 1-year rates of cardiac death/MI, MI, and
TVR than BMS, lower 1-year rates of TVR than PC-ZES,
and improved long-term outcomes compared with BMS and
PES; 2) although there were no signiﬁcant differences in the
risk of cardiac death/MI, MI, and TVR between BP-BES
and other second-generation DES (CoCr-EES, PtCr-
EES, and slow-release zotarolimus-eluting stent), BP-BESwere associated with higher rates of 1-year and long-term
deﬁnite ST compared with CoCr-EES; and 3) signiﬁcant
time-related differences in ST were apparent between
different stent types, with CoCr-EES being associated with
the lowest rates of ST in the early and late periods, and PES
and SES having the highest risk of very late ST.
Studies have shown that permanent polymers coating
ﬁrst-generation DES are associated with chronic inﬂam-
mation and delayed arterial healing, which might be
responsible for the higher rates of very late ST observed
with ﬁrst-generation DES compared with BMS (4,5).
These ﬁndings prompted the development of safer DPs as
well as BPs. The theoretical advantage of BP-DES is to
eliminate the potential for polymer-related triggers for late
and very late ST. Among BP-based DES, BP-BES has
received the most extensive investigation. Several RCTs
have investigated the safety and efﬁcacy of BP-BES
compared with SES (14,15), BMS (6), and more recently
with CoCr-EES (9). However, all these studies were
powered for non-inferiority for composite endpoints and
were not sized sufﬁciently to reveal potential differences in
low-frequency endpoints such as cardiac mortality, MI, and
ST. With more than 85,000 randomized patients, our
study has sufﬁcient power to reveal important safety and
efﬁcacy differences between BP-based DES and other stent
types.
Figure 3 Pooled HR and 95% CIs/100 Patient-Years of BES Versus Other Stent Types
Pooled hazard ratio (HR) and 95% CIs/100 patient-years of BES versus other stent types determined by Poisson’s regression analysis for (A) cardiac death or myocardial
infarction; (B) myocardial infarction; (C) target vessel revascularization (TVR); (D) deﬁnite stent thrombosis; and (E) deﬁnite/probable stent thrombosis. Abbreviations as in
Figure 1. Continued on the next page.
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304The main ﬁnding of this study is that BP-BES were
associated with improved outcomes compared with BMS
and ﬁrst-generation DES (especially PES) and similar rates
of death, cardiac death, cardiac death/MI, MI, and TVR
compared with other second-generation DES but with
higher rates of 1-year and long-term deﬁnite ST compared
with CoCr-EES. The increased risk for deﬁnite ST with
BP-BES compared with CoCr-EES was apparent both in
the early period (before 30 days) and the late period
(between 30 days and 1 year). Conversely, a nonsigniﬁcanttrend was present for a reduced rate of very late ST (beyond
1 year) with BP-BES compared with CoCr-EES (OR:
2.46), although the conﬁdence interval around this point
estimate was wide due to insufﬁcient data, and this trend did
not offset the signiﬁcant reduction in early and late ST with
CoCr-EES. Similar results were apparent when the less-
speciﬁc deﬁnition of deﬁnite/probable ST was considered,
but the precision of the point estimate was reduced.
These data demonstrate that use of BP might not be
associated with the lowest risk of ST, especially within the
Figure 3 Continued
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305ﬁrst year after stent implantation. Polymers requiring active
bioresorption have historically been associated with greater
rates of inﬂammation than DP (16,17). Conversely, in vitro
studies have shown that the durable ﬂuorinated co-polymer
coating CoCr-EES and PtCr-EES is less thrombogenic
and causes less platelet activation compared with other
polymers (18,19) or even an uncoated metallic stent surface
(20). The results of the present study are consistent with
the hypothesis that any potential advantages of BP-based
DES over biocompatible DP-based stents might not
emerge until the late follow-up period after biodegradation
of the polymer. However, prior studies have shown that
most ST episodes occur within the ﬁrst 30 days after
implantation (21,22). Thus, large-scale studies will be
required to determine whether the potential late beneﬁts of
a BP can more than offset the early beneﬁts of a throm-
boresistant DP. In this regard, the extent to which the DP
provides clinically important thromboresistant properties in
the very late period is undetermined. Moreover, although
polylactic acid (the BP used in the Biomatrix and Nobori
stents [Terumo Corporation] in the present report) induces
relatively low levels of inﬂammation, other BP might
theoretically be more inert and/or completely resorb faster
(e.g., in 3 months compared with 6 to 9 months in the
current BP-BES), permitting the late beneﬁts of BP-DES
to emerge at an earlier time period (23).Of note, SES and PES were associated with the highest
rates of ST beyond 1 year, signiﬁcantly higher than with
BMS, BP-BES, CoCr-EES, and PC-ZES. Thus, some of
the late beneﬁt seen in randomized trials of BP-BES
compared with ﬁrst-generation DES (24) might relate
more to the poor safety proﬁle of the comparator stent
rather than to speciﬁc beneﬁts of the BP itself. This
observation reinforces the need for large-scale randomized
trials between BP-BES and best-in-class second-generation
DES to determine whether meaningful differences are
present between these 2 devices. To date, only 1 such study
has been performed, the COMPARE II (Comparison of
the Everolimus Eluting With the Biolimus A9 Eluting
Stent) trial in which 2,707 patients were randomized to
BP-BES versus CoCr-EES (9). Unfortunately, the low
event rates observed in this trial (one-half of that expected)
precluded determining whether the nonsigniﬁcant differ-
ences in event rates between the 2 stents observed in this
trial at 1 year are in fact real (type II error) or whether they
would diminish with greater patient recruitment. In addi-
tion, longer-term follow-up is required for possible late
differences to emerge.
In the present study BP-BES were associated with
a signiﬁcant reduction not only in TVR but also in cardiac
death/MI,MI, andST comparedwithBMS.This observation
has previously been reported with other second-generation
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306DES (11). The signiﬁcant reduction in cardiac death and
MI is probably due both to the lower risk of early ST and
the lower risk of restenosis and TVR compared with BMS,
which can present as a MI in up to 20% of patients (25,26).
These beneﬁts did not translate to lower rates of death or
cardiac death with either BP-BES or second-generation DES
but likely reﬂect the multifactorial causes of death in these
patients.
Study limitations. As with any meta-analysis, our report
shares the limitations of the original studies. Moreover, by
exploiting potentially complex evidence network and indi-
rect comparisons as well as direct comparisons, network
meta-analysis assumes that patients enrolled in the studies
could have been sampled from the same theoretical pop-
ulation and that similar comparators between different trials
have a consistent risk-beneﬁt ratio. Duration of dual anti-
platelet therapy in patients treated with DES and BMS
differed across trials, thus representing a possible con-
founding factor. Results were analyzed on aggregate data,
and therefore we could not assess whether all baseline
characteristics were balanced between the groups (although
for the most part they were within each RCT). The
observed risk ratios with the PtCr-EES in most cases
tracked that of CoCr-EES compared with other stent
types, although with wide conﬁdence intervals, likely due to
the relatively small number of enrolled patients contributing
data to the PtCr-EES. This might explain why signiﬁcant
differences did not emerge for the PtCr-EES despite use of
the same polymer, drug, and release kinetics as the CoCr-
EES. Finally, follow-up data for CoCr-EES in studies to
date are mostly limited to 2 years. Indeed, the advantage of
BP-based DES over DP-based DES is expected to emerge
in the late follow-up, and therefore whether the observed
differences would change with more extended follow-up is
unknown.Conclusions
Our study suggests that stents eluting biolimus from BP are
associated with superior clinical outcomes compared with
BMS and ﬁrst-generation DES and similar rates of cardiac
death/MI, MI, and TVR compared with second-generation
DP-DES but higher rates of deﬁnite ST than CoCr-EES.
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